摘要
目的探讨重组人血小板生成素联合白介素治疗白血病患儿化疗后血小板减少症的临床效果。方法60例白血病化疗后血小板减少症患儿随机分为两组,对照组采用白介素-11治疗,观察组采用重组人血小板生成素联合白介素-11治疗,比较两组的治疗效果、治疗指标及用药安全性。结果治疗后,观察组的总有效率高于对照组,血小板复常时间及用药治疗时间均短于对照组(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组人血小板生成素联合白介素治疗白血病患儿化疗后血小板减少症的临床效果较好,可有效缩短用药时间,且不会明显增加不良反应发生风险。
Objective To explore the clinical effect of recombinant human thrombopoietin combined with interleukin in the treatment of thrombocytopenia after chemotherapy in children with leukemia.Methods 60 children with thrombocytopenia after chemotherapy for leukemia were randomly divided into two groups.The control group was treated with interleukin-11,and the observation group was treated with recombinant human thrombopoietin combined with interleukin-11.The therapeutic effect,treatment indicators and medication safety were compared between the two groups.Results After treatment,the total effective rate of the observation group was higher than that of the control group,and the platelet recovery time and medication time were shorter than those of the control group(P<0.05).No significant difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Recombinant human thrombopoietin combined with interleukin in the treatment of thrombocytopenia after chemotherapy in children with leukemia has good clinical effect,which can shorten the medication time without significantly increasing the occurrence risk of adverse reactions.
作者
翟素花
刘江华
ZHAI Suhua;LIU Jianghua(Department of Hematology and Oncology,the Children's Hospital Affiliated to Zhengzhou University/He'nan Children's Hospital,Zhengzhou 450018,China)
出处
《临床医学工程》
2023年第2期203-204,共2页
Clinical Medicine & Engineering
关键词
重组人血小板生成素
白介素
白血病
化疗
血小板减少症
Recombinant human thrombopoietin
Interleukin
Leukemia
Chemotherapy
Thrombocytopenia
